Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Superluminal Medicines secures $60m to advance rare obesity therapy | PharmaVoice

Pharma Tech

Superluminal Medicines secures $60m to advance rare obesity therapy

Sep 4, 2026, 9:18 AM

Read Full Article → Superluminal Medicines secures $60m to advance rare obesity therapy

Superluminal Medicines secures $60m to advance rare obesity therapy

Translate article text

Choose a language and wait for the translated text.

Superluminal Medicines has completed a $60m Series B round to support its research into therapies for rare genetic forms of obesity.